leukemic gene expression regulation

Summary

Summary: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in leukemia.

Top Publications

  1. pmc Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia
    Teresa Palomero
    Institute for Cancer Genetics, Columbia University, New York, New York 10032, USA
    Nat Med 13:1203-10. 2007
  2. ncbi Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia
    Stefan Schmidt
    Tyrolean Cancer Research Institute, Innrain 66, A 6020 Innsbruck, Austria
    Blood 107:2061-9. 2006
  3. pmc Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
    George Adrian Calin
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Proc Natl Acad Sci U S A 99:15524-9. 2002
  4. pmc miR-15 and miR-16 induce apoptosis by targeting BCL2
    Amelia Cimmino
    Department of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus OH 43210, USA
    Proc Natl Acad Sci U S A 102:13944-9. 2005
  5. ncbi High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics
    Michael Heuser
    British Columbia Cancer Research Centre, 675 West 10th Ave, Vancouver, BC, Canada
    Blood 108:3898-905. 2006
  6. ncbi Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping
    C Haferlach
    MLL Munich Leukemia Laboratory, Munich, Germany
    Leukemia 21:2442-51. 2007
  7. pmc Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells
    Esther Hulleman
    Department of Pediatric Oncology and Hematology, Erasmus Medical Center Sophia Children s Hospital, University Medical Center, Rotterdam, The Netherlands
    Blood 113:2014-21. 2009
  8. ncbi CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment
    Piers E M Patten
    Department of Haematological and Molecular Medicine, King s College London, Rayne Institute, London, USA
    Blood 111:5173-81. 2008
  9. pmc Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1
    Bas J Wouters
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 110:3706-14. 2007
  10. ncbi MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
    Scott A Armstrong
    Departments of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Nat Genet 30:41-7. 2002

Detail Information

Publications214 found, 100 shown here

  1. pmc Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia
    Teresa Palomero
    Institute for Cancer Genetics, Columbia University, New York, New York 10032, USA
    Nat Med 13:1203-10. 2007
    ....
  2. ncbi Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia
    Stefan Schmidt
    Tyrolean Cancer Research Institute, Innrain 66, A 6020 Innsbruck, Austria
    Blood 107:2061-9. 2006
    ....
  3. pmc Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
    George Adrian Calin
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Proc Natl Acad Sci U S A 99:15524-9. 2002
    ..Detailed deletion and expression analysis shows that miR15 and miR16 are located within a 30-kb region of loss in CLL, and that both genes are deleted or down-regulated in the majority ( approximately 68%) of CLL cases...
  4. pmc miR-15 and miR-16 induce apoptosis by targeting BCL2
    Amelia Cimmino
    Department of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus OH 43210, USA
    Proc Natl Acad Sci U S A 102:13944-9. 2005
    ..BCL2 repression by these microRNAs induces apoptopsis in a leukemic cell line model. Therefore, miR-15 and miR-16 are natural antisense Bcl2 interactors that could be used for therapy of Bcl2-overexpressing tumors...
  5. ncbi High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics
    Michael Heuser
    British Columbia Cancer Research Centre, 675 West 10th Ave, Vancouver, BC, Canada
    Blood 108:3898-905. 2006
    ..In conclusion, our data suggest MN1 overexpression as a new prognostic marker in AML with normal cytogenetics...
  6. ncbi Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping
    C Haferlach
    MLL Munich Leukemia Laboratory, Munich, Germany
    Leukemia 21:2442-51. 2007
    ..Therefore, prospective clinical trials should evaluate the prognostic impact of newly available CBA data...
  7. pmc Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells
    Esther Hulleman
    Department of Pediatric Oncology and Hematology, Erasmus Medical Center Sophia Children s Hospital, University Medical Center, Rotterdam, The Netherlands
    Blood 113:2014-21. 2009
    ..Together, these findings indicate the importance of the glycolytic pathway in glucocorticoid resistance in ALL and suggest that targeting glycolysis is a viable strategy for modulating prednisolone resistance in ALL...
  8. ncbi CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment
    Piers E M Patten
    Department of Haematological and Molecular Medicine, King s College London, Rayne Institute, London, USA
    Blood 111:5173-81. 2008
    ....
  9. pmc Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1
    Bas J Wouters
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 110:3706-14. 2007
    ..A gene expression prediction signature allowed the detection of similar cases of leukemia in independent series of AML...
  10. ncbi MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
    Scott A Armstrong
    Departments of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Nat Genet 30:41-7. 2002
    ..Establishing that MLL is a unique entity is critical, as it mandates the examination of selectively expressed genes for urgently needed molecular targets...
  11. ncbi Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia
    Jaewon Choi
    Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon Dong, Kangnam Ku, Seoul, South Korea 135 710
    Blood 109:471-7. 2007
    ..049). This study suggests that Livin expression is a novel prognostic marker in childhood ALL and thus needs to be incorporated into the patient stratification and treatment protocols...
  12. ncbi Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias
    H Honda
    Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Tokyo, Japan
    Blood 91:2067-75. 1998
    ....
  13. ncbi Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells
    Wim J E Tissing
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Dr Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands
    Blood 109:3929-35. 2007
    ..Biologic characterization of these genes and pathways might elucidate the action of glucocorticoids in ALL cells, possibly suggesting causes of glucocorticoid resistance and new potential targets for therapy...
  14. ncbi HERG K+ channel expression in CD34+/CD38-/CD123(high) cells and primary leukemia cells and analysis of its regulation in leukemia cells
    Huiyu Li
    Center for Stem Cell Research and Application, Institute of Hematology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiegang Avenue, 430022 Wuhan, China
    Int J Hematol 87:387-92. 2008
    ..These data provide evidence for the oncogenic potential of HERG K+ channels and it may be a novel, potential pharmacological target for leukemia therapy in the future...
  15. ncbi MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia
    Mojca Jongen-Lavrencic
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 111:5078-85. 2008
    ..MicroRNA expression apparently bears specific relationships to the heterogeneous pathobiology of AML. Distinctive microRNA signatures appear of potential value in the clinical diagnosis of AML...
  16. ncbi Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein
    Francesco Fazi
    Department of Histology and Medical Embryology, University La Sapienza, Rome, 00161, Italy
    Cancer Cell 12:457-66. 2007
    ..Here, we identify an additional action for a leukemia fusion protein linking the epigenetic silencing of a microRNA locus to the differentiation block of leukemia...
  17. pmc MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
    Ramiro Garzon
    Department of Medicine, Ohio State University, Columbus, 43210, USA
    Blood 113:6411-8. 2009
    ....
  18. ncbi Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression
    María J Bueno
    Cell Division and Cancer Group, Centro Nacional de Investigaciones Oncologicas CNIO, E 28029 Madrid, Spain
    Cancer Cell 13:496-506. 2008
    ..Thus, miR-203 functions as a tumor suppressor, and re-expression of this microRNA might have therapeutic benefits in specific hematopoietic malignancies...
  19. ncbi Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia
    Valter Gattei
    Clinical and Experimental Onco Hematology Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico Aviano, Italy
    Blood 111:865-73. 2008
    ..95; P=.002) cases. These findings support the introduction of CD49d detection in routine prognostic assessment of CLL patients, and suggest both pathogenetic and therapeutic implications for CD49d expression in CLL...
  20. ncbi Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia
    Clemens Grabher
    Department of Pediatric Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Rev Cancer 6:347-59. 2006
    ..The recent discovery of novel activating mutations in NOTCH1 in more than 50% of human T-ALL samples has made it clear that Notch 1 is far more important in human T-ALL pathogenesis than previously suspected...
  21. ncbi The HOXD11 gene is fused to the NUP98 gene in acute myeloid leukemia with t(2;11)(q31;p15)
    Takeshi Taketani
    Department of Pediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, 113 8655, Japan
    Cancer Res 62:33-7. 2002
    ....
  22. ncbi Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia
    Y Liu
    Radiumhemmet, Karolinska Hospital, Stockholm, Sweden
    Oncogene 15:2463-73. 1997
    ..We conclude that the Leu1 and Leu2 genes are strong candidates as tumor suppressor gene(s) involved in B-CLL leukemogenesis...
  23. ncbi High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated
    Sanne Lugthart
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 111:4329-37. 2008
    ..001 and event-free survival [EFS]: P = .002). We argue that EVI1/ME quantitative expression analysis should be implemented in the molecular diagnostic procedures of AML...
  24. ncbi Complexity of miR-223 regulation by CEBPA in human AML
    Marianne Eyholzer
    Institute of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 10, 3010 Bern, Switzerland
    Leuk Res 34:672-6. 2010
    ..Our results suggest that miR-223 suppression in AML is caused by impaired miR-223 upstream factors...
  25. pmc Karyotype-specific microRNA signature in chronic lymphocytic leukemia
    Rosa Visone
    Department of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Blood 114:3872-9. 2009
    ..Thus, the use of the microRNA-based classifications may yield clinically useful biomarkers of tumor behavior in CLL...
  26. ncbi Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia
    A Migliazza
    Institute of Cancer Genetics, Columbia University, New York, New York 10032, USA
    Blood 97:2098-104. 2001
    ..However, haplo-insufficiency of one of the identified genes may contribute to tumorigenesis. (Blood. 2001;97:2098-2104)..
  27. ncbi Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia
    Adolfo A Ferrando
    Department of Pediatric Oncology, Dana Farber Cancer Institute Harvard School of Public Health, 44 Binney Street, Mayer 630, Boston 02115, MA, USA
    Lancet 363:535-6. 2004
    ..Furthermore, our findings lead to questions about whether stem-cell transplantation in first remission is necessary for effective treatment of patients in the low-risk subgroup of patients with TLX1 oncogene expression...
  28. ncbi Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation
    Sabina Chiaretti
    Department of Medical Oncology and Biostatistical Science, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 11:7209-19. 2005
    ..To characterize gene expression signatures in acute lymphocytic leukemia (ALL) cells associated with known genotypic abnormalities in adult patients...
  29. ncbi Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML
    Sahar Barjesteh van Waalwijk van Doorn-Khosrovani
    Institute of Hematology, Erasmus Medical Centre, Rotterdam, The Netherlands
    Hematol J 4:31-40. 2003
    ..By including this newly developed PCR assay, we define a subgroup of good-risk patients within the heterogeneous intermediate-risk group of AML...
  30. ncbi Chronic myelogenous leukemia molecular signature
    Michal Oskar Nowicki
    Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA
    Oncogene 22:3952-63. 2003
    ..Altogether, this work provides a large body of information regarding gene expression profiles associated with CML and also represents a source of potential targets for CML therapeutics...
  31. ncbi Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia
    Jose Roman-Gomez
    Department of Hematology, Hospital Reina Sofia, Cordoba, Spain
    Blood 109:3462-9. 2007
    ..001) and overall survival (28% versus 61% respectively, P = .001). Our results indicate a role of abnormal Wnt signaling in ALL and establish a group of patients with a significantly worse prognosis (methylated group)...
  32. pmc Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group
    Stuart S Winter
    Department of Pediatrics, The University of New Mexico Health Sciences Center, Albuquerque, NM 87131 5311, USA
    Blood 110:1429-38. 2007
    ..Genetic profiling may identify T-ALL patients who are likely to fail induction and for whom alternate treatment strategies might be beneficial...
  33. ncbi High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia
    Alejo A Morales
    Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden
    Int J Cancer 113:730-7. 2005
    ..05). We conclude that bfl-1 may be an important regulator of B-CLL apoptosis, which could contribute to disease progression and resistance to chemotherapy, and as such represent a future potential therapeutic target...
  34. ncbi Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia
    Corine J Hess
    Department of Haematology, VU University Medical Center, Amsterdam, The Netherlands
    Leuk Lymphoma 49:1132-41. 2008
    ..In addition, ESR1 methylation may reflect a biological pathway that leads to hypermethylation of multiple genes, which is reflected by methylation of IGSF4 and/or CDKN2B/p15...
  35. ncbi Oncogenic transcription factors in the human acute leukemias
    A T Look
    Department of Experimental Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA 38163, USA
    Science 278:1059-64. 1997
    ..The insights gained from studies of translocation-generated oncogenes and their protein products should hasten the development of highly specific, and hence less toxic, forms of leukemia therapy...
  36. ncbi Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia
    H Mabuchi
    Kimmel Cancer Center, Thomas Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA
    Cancer Res 61:2870-7. 2001
    ....
  37. ncbi The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis?
    Kylie D Mason
    Department of Diagnostic Haematology, Royal Melbourne Hospital, Grattan St, Parkville, Vic, Australia
    Blood Rev 20:71-82. 2006
    ..Further analysis with the inclusion of novel antibodies and the combination of multiple antibodies to create further subgroups such as the panmyeloid phenotype will continue to enhance knowledge in this area...
  38. ncbi Gene expression profiles in a panel of childhood leukemia cell lines mirror critical features of the disease
    Ursula R Kees
    Telethon Institute for Child Health Research, The University of Western Australia, Perth, Australia and National Human Genome Research Institute, NIH, Bethesda, Maryland 20892, USA
    Mol Cancer Ther 2:671-7. 2003
    ..Importantly, the panel of lines displayed the critical genetic features identified in clinically important acute lymphoblastic leukemia subtypes in childhood leukemia patients...
  39. ncbi Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study
    Riccardo Bomben
    Clinical and Experimental Onco Haematology Unit, Centro di Riferimento Oncologico, I R C C S, Aviano PN, Italy
    Br J Haematol 144:492-506. 2009
    ..Altogether, our analysis identified additional molecular and clinical features for CLL expressing stereotyped BCR...
  40. pmc Differential and common leukemogenic potentials of multiple NUP98-Hox fusion proteins alone or with Meis1
    Nicolas Pineault
    Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver V5Z 1L3, Canada
    Mol Cell Biol 24:1907-17. 2004
    ..Our results support a model in which many if not all Hox genes can be leukemogenic and point to striking functional overlap not previously appreciated, presumably reflecting common regulated pathways...
  41. pmc A virus-encoded telomerase RNA promotes malignant T cell lymphomagenesis
    Sascha Trapp
    Department of Microbiology and Immunology, Cornell University, Ithaca, NY 14853, USA
    J Exp Med 203:1307-17. 2006
    ..We concluded that vTR plays a critical role in MDV-induced T cell lymphomagenesis. Furthermore, our results provide the first description of tumor-promoting effects of TR in a natural virus-host infection model...
  42. ncbi Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia
    Yasunori Nakagawa
    Department of Pathology and Immunology, Aging and Developmental Sciences, Graduate School, Tokyo Medical and Dental University, 1 5 45 Yushima, Bunkyo ku, Tokyo 113 8519, Japan
    Leuk Res 28:487-94. 2004
    ....
  43. ncbi CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors
    T Palomero
    Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA
    Leukemia 20:1279-87. 2006
    ....
  44. ncbi The role of HOX genes in malignant myeloid disease
    Elizabeth A Eklund
    The Feinberg School at Northwestern University and Jesse Brown VHA Medical Center, Chicago, Illinois 60611, USA
    Curr Opin Hematol 14:85-9. 2007
    ..The purpose of this review is to outline recent progress in understanding the role that dysregulation of HOX-gene expression plays in the pathogenesis of myeloid leukemogenesis...
  45. ncbi Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia
    Susan M O'Brien
    M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030 7305, USA
    J Clin Oncol 23:7697-702. 2005
    ..To determine the maximum-tolerated dose (MTD), efficacy, safety, and pharmacokinetics of oblimersen sodium in patients with advanced chronic lymphocytic leukemia (CLL)...
  46. ncbi Pattern robustness of diagnostic gene expression signatures in leukemia
    Alexander Kohlmann
    Laboratory for Leukemia Diagnostics, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
    Genes Chromosomes Cancer 42:299-307. 2005
    ....
  47. ncbi New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes
    A Kohlmann
    Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig Maximilians University, 81377 Munich, Germany
    Leukemia 19:953-64. 2005
    ..Taken together, the identified molecular expression pattern of MLL fusion gene samples and biological networks revealed new insights into the aberrant transcriptional program in 11q23/MLL leukemias...
  48. pmc The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy
    Susan P Whitman
    Department of Internal Medicine, Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Blood 106:345-52. 2005
    ....
  49. ncbi Hox regulation of normal and leukemic hematopoietic stem cells
    Carolina Abramovich
    Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Curr Opin Hematol 12:210-6. 2005
    ....
  50. pmc HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses
    Cristina Scielzo
    Department of Oncology, Universita Vita e Salute San Raffaele, Milan, Italy
    J Clin Invest 115:1644-50. 2005
    ..These data indicate a central role for antigen stimulation in CLL and suggest a new therapeutic target for patients with aggressive disease...
  51. ncbi Variation of LEF-1 mRNA expression in low-grade B-cell non-Hodgkin's lymphoma
    Denise Howe
    Leukaemia Research Laboratory, Taunton and Somerset NHS Trust, Musgrove Park Hospital, Taunton, Somerset TA1 5DA, UK
    Leuk Res 30:29-32. 2006
    ..This suggests that there exist key differences in the activity of the Wnt/beta-catenin pathway between low-grade B-cell malignancies...
  52. ncbi Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia
    Maria Ilaria Del Principe
    Cattedra di Ematologia, Universita Tor Vergata, Ospedale S Eugenio, Via Fiume Giallo, 430 MA, 00144 Roma, Rome, Italy
    Blood 108:853-61. 2006
    ..On this line, we recommend and are also interested in conducting a prospective randomized trial of early intervention versus observation for ZAP-70(+) patients...
  53. ncbi CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia
    Pär Josefsson
    The Leukemia Laboratory, Department of Hematology, Rigshospitalet and University of Copenhagen, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    Blood 109:4973-9. 2007
    ..Only CLLU1 expression and IgV(H) mutational status had independent predictive power. Thus, analysis of CLLU1 expression is highly applicable in risk prediction in CLL for patients of an age eligible for risk stratification...
  54. ncbi CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype
    Hong Chang
    Department of Laboratory Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, 610 University Avenue, 4 320, Toronto, Ont, Canada M5G 2M9
    Leuk Res 31:157-62. 2007
    ..003 and P=0.0157, respectively) and shorter OS (P</=0.001 and P=0.007, respectively). Multivariate analysis of age, WBC, CD34, HLA-DR and CD7 showed that CD7 expression was an independent risk factor for DFS (P=0.01) and PRS (P=0.02)...
  55. ncbi Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation
    Hitoshi Kiyoi
    Department of Infectious Diseases, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Int J Hematol 83:301-8. 2006
    ....
  56. ncbi Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients
    A Kohlmann
    Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig Maximilians University, Munich, Germany
    Leukemia 18:63-71. 2004
    ..As such, previously reported gene expression patterns identified by microarray technology are validated and confirmed on truly independent leukemia patient samples...
  57. ncbi Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration
    Katja Haas
    Department of Medical Genetics, Medical University of Vienna, Vienna, Austria
    Genes Chromosomes Cancer 47:288-98. 2008
    ..This article contains Supplementary Material available at http://www.interscience.wiley.com/jpages/1045-2257/suppmat...
  58. ncbi Repression of the BH3-only molecule PMAIP1/Noxa impairs glucocorticoid sensitivity of acute lymphoblastic leukemia cells
    Christian Ploner
    Division Molecular Pathophysiology, Biocenter, Medical University of Innsbruck, Fritz Pregl Strasse 3, 6020, Innsbruck, Austria
    Apoptosis 14:821-8. 2009
    ..Interfering with the anti-apoptotic component of the GC response might contribute to improved therapeutic approaches and circumvention of resistance to this therapy...
  59. ncbi CD38 at the junction between prognostic marker and therapeutic target
    Silvia Deaglio
    Department of Genetics, Laboratory of Immunogenetics, Biology and Biochemistry and CERMS, Via Santena 19, 10126 Torino, Italy
    Trends Mol Med 14:210-8. 2008
    ..The use of reagents specifically blocking the molecule might provide a new approach for interfering with deleterious growth circuits, therefore increasing the susceptibility of leukemic cells to conventional chemotherapy...
  60. ncbi The role of microRNAs in normal hematopoiesis and hematopoietic malignancies
    J Kluiver
    Department of Pathology and Laboratory Medicine, Section Pathology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    Leukemia 20:1931-6. 2006
    ..In this review, we report on the biological relevance of miRNAs for the differentiation of normal hematopoietic cells and on the contribution of deregulated miRNA expression in their malignant counterparts...
  61. ncbi Differential expression of TCL1 during pre-B-cell acute lymphoblastic leukemia progression
    S Fears
    Section of Hematology, Oncology Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Cancer Genet Cytogenet 135:110-9. 2002
    ..TCL1 expression was correlated with TEL expression by reintroducing TEL into AT-2 cells and demonstrating that those cells expressing TEL at high levels showed a decreased expression of endogenous TCL1...
  62. ncbi Classification of pediatric acute lymphoblastic leukemia by gene expression profiling
    Mary E Ross
    Department of Hematology Oncology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Blood 102:2951-9. 2003
    ....
  63. ncbi Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion
    Belinda Austen
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, United Kingdom
    J Clin Oncol 25:5448-57. 2007
    ..Our aim was to determine if CLL tumors with a chromosome 11q deletion might be divided into two subgroups based on the status of the remaining ATM allele...
  64. ncbi Functional analyses of Src-like adaptor (SLA), a glucocorticoid-regulated gene in acute lymphoblastic leukemia
    Muhammad Mansha
    Division Molecular Pathophysiology, Biocenter, Medical University of Innsbruck, Innsbruck 6020, Austria
    Leuk Res 34:529-34. 2010
    ..Although SLA is a prominent GC response gene, it does not seem to contribute to the anti-leukemic effects of GC...
  65. ncbi Epigenetic analysis of childhood acute lymphoblastic leukemia
    Thomas L Dunwell
    Institute of Biomedical Research, Medical School, University of Birmingham, Edgbaston, Birmingham, UK
    Epigenetics 4:185-93. 2009
    ..The identification of frequently methylated genes showing cancer specific methylation will be useful in developing early cancer detection screens and for targeted epigenetic therapies...
  66. ncbi NUP98 is fused to PMX1 homeobox gene in human acute myelogenous leukemia with chromosome translocation t(1;11)(q23;p15)
    T Nakamura
    PRESTO, Japan Science and Technology Corp, Tokyo, Japan The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
    Blood 94:741-7. 1999
    ..These findings suggest that constitutive expression and alteration of the transcriptional activity of the PMX1 homeodomain protein may be critical for myeloid leukemogenesis...
  67. ncbi Glucocorticoid receptor heterozygosity combined with lack of receptor auto-induction causes glucocorticoid resistance in Jurkat acute lymphoblastic leukemia cells
    S Riml
    Division of Molecular Pathophysiology, Institute of Pathophysiology, University of Innsbruck Medical School, Fritz Pregl Str 3, A 6020 Innsbruck, Austria
    Cell Death Differ 11:S65-72. 2004
    ..Absent GR auto-induction could not be restored by transgenic GR and, hence, was not caused by reduced basal GR levels. Thus, inactivation of one GR gene results in haploinsufficiency if associated with lack of GR auto-induction...
  68. ncbi Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia
    William Tse
    Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington School of Medicine, Seattle, USA
    Blood 104:3058-63. 2004
    ..01). AF1q expression may correlate with clinical outcome in pediatric AML, although it is not clear if AF1q is simply a marker of a more primitive phenotype or contributes directly to leukemogenesis...
  69. pmc Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 26:5078-87. 2008
    ....
  70. ncbi Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia
    Liguang Chen
    Division of Hematology Oncology, Department of Medicine, University of California, San Diego for the CLL Research Consortium, San Diego, CA, USA
    Blood 100:4609-14. 2002
    ....
  71. ncbi Hox expression in AML identifies a distinct subset of patients with intermediate cytogenetics
    J Roche
    CNRS UMR 6187, Universite de Poitiers, 40 Av du Recteur Pineau, Poitiers, Cedex, France
    Leukemia 18:1059-63. 2004
    ..The apparent global upregulation of HOX expression could be due to growth-factor signaling or, alternatively, these patterns may reflect a particular stage of differentiation of the leukemic cells...
  72. ncbi Survival of leukemic B cells promoted by engagement of the antigen receptor
    A Bernal
    Immunology Program, Weill Graduate School of Medical Sciences of Cornell University, and Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    Blood 98:3050-7. 2001
    ....
  73. ncbi Altered glucose metabolism in childhood pre-B acute lymphoblastic leukaemia
    J M Boag
    Division of Children s Leukaemia and Cancer Research, Telethon Institute for Child Health Research, Perth, Western Australia, Australia
    Leukemia 20:1731-7. 2006
    ..The finding offers new options for targeted therapy for ALL patients...
  74. ncbi BCR-ABL down-regulates the DNA repair protein DNA-PKcs
    E Deutsch
    , Institut Gustave Roussy, Villejuif, France
    Blood 97:2084-90. 2001
    ..The down-regulation of DNA-PKcs was reversible in CD34(+) CML cells suggesting that this approach might offer a novel and powerful therapeutic strategy in this disease, especially to delay the blast crisis. (Blood. 2001;97:2084-2090)..
  75. ncbi Glucocorticoid-regulated microRNAs and mirtrons in acute lymphoblastic leukemia
    J Rainer
    Tyrolean Cancer Research Institute, Innsbruck, Austria
    Leukemia 23:746-52. 2009
    ..Thus, the observed complex changes in miRNA/mirtron expression during GC treatment might contribute to the anti-leukemic GC effects in a cell context-dependent manner...
  76. ncbi BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?
    L Legros
    Leukemia 21:2204-6. 2007
  77. ncbi Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides
    Karl J Aichberger
    Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, AKH Wien, Waehringer Guertel 18 20, A 1097 Vienna, Austria
    Blood 105:3303-11. 2005
    ..Moreover, the mcl-1 ASO was found to synergize with imatinib in producing growth inhibition in these cells. Together, our data identify MCL-1 as a BCR/ABL-dependent survival factor and interesting target in CML...
  78. pmc Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemia
    Sally L Rogers
    Terry Fox Laboratory, British Columbia Cancer Agency, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada
    Mol Cancer 9:41. 2010
    ..However, little is known about the mechanisms that underlie the variable expression of these genes in the leukemic cells...
  79. ncbi A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosis-inducing ligand (TRAIL) through 15-deoxy-Delta 12, 14 prostaglandin J2 production
    Hiroo Hasegawa
    Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
    Blood 110:1664-74. 2007
    ..These results indicate that 15d-PGJ(2) sensitizes TRAIL-resistant cells to TRAIL in a PPAR gamma-independent manner and that the use of 15d-PGJ(2) or its inducers, such as FCB, is a new strategy for cancer therapy...
  80. ncbi Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis
    Sabina Chiaretti
    Division of Hematology, Department of Cellular Biotechnologies and Hematology, University La Sapienza, Rome, Italy
    Haematologica 92:619-26. 2007
    ..We sought to evaluate whether T-ALL patients with overexpression of ABL showed a peculiar gene expression pattern and were characterized by having specific rearrangements...
  81. ncbi Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response
    Laurence Lagneaux
    Experimental Hematology, Bordet Institute, ULB, Brussels, Belgium
    Exp Hematol 35:1527-37. 2007
    ..The effects of valproic acid (VPA), an antiepileptic drug with histone deacetylase inhibitory activity, on mononuclear cells isolated from 40 CLL patients were evaluated...
  82. ncbi Effect of ionizing radiation on cellular procoagulability and co-ordinated gene alterations
    Petra Goldin-Lang
    Department of Cardiology and Pneumology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Haematologica 92:1091-8. 2007
    ..Our study examined whether IR induced tissue factor (TF) expression and procoagulability. We further investigated coordinated gene alterations associated with TF upregulation in the myelomonocytic leukemia THP-1 cells...
  83. ncbi Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells
    E Svensson
    Division of Hematology and Transfusion Medicine, Faculty of Medicine, Lund University, Lund, Sweden
    Leukemia 21:2485-94. 2007
    ..Our data demonstrate that WT1 expression is induced by oncogenic signalling from BCR/ABL1 and that WT1 contributes to resistance against apoptosis induced by imatinib...
  84. ncbi Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells
    Kyu Tae Kim
    Department of Oncology, Johns Hopkins University School of Medicine, Bethesda, MD, USA
    Br J Haematol 138:603-15. 2007
    ..The alterations of the gene expression profiles in these cells help to further elucidate the mechanisms of FLT3-mediated leukaemogenesis...
  85. ncbi Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia
    A Tonks
    Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK
    Leukemia 21:2495-505. 2007
    ..These data provide the most comprehensive and pertinent assessment of the effect of RUNX1-RUNX1T1 on gene expression and demonstrate the highly context-dependent effects of this fusion gene...
  86. ncbi The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines
    Ayse Batova
    Division of Pediatric Hematology Oncology, Department of Pediatrics, Medical Center, University of California San Diego, 200 West Arbor Drive, San Diego, CA 92103 8447, USA
    Blood 100:3319-24. 2002
    ..Collectively, our results suggest that AN-9 is a selective agent for hematopoietic malignancies that can circumvent the mechanisms of chemoresistance limiting most conventional chemotherapy...
  87. pmc The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy
    Y Ge
    Developmental Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
    Leukemia 22:521-9. 2008
    ....
  88. pmc Topoisomerase IIbeta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance
    Suzan McNamara
    Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, Segal Cancer Center, 3755 Chemin de la Cote Ste Catherine, Montreal, Quebec, Canada
    Mol Cell Biol 28:2066-77. 2008
    ..Our results identify a novel mechanism of resistance in APL and provide further insight to the role of TopoIIbeta in gene regulation and differentiation...
  89. pmc Altered gene expression in busulfan-resistant human myeloid leukemia
    Benigno C Valdez
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, United States
    Leuk Res 32:1684-97. 2008
    ....
  90. ncbi Linkage of Meis1 leukemogenic activity to multiple downstream effectors including Trib2 and Ccl3
    Bob Argiropoulos
    Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Exp Hematol 36:845-59. 2008
    ..MEIS1, a HOX cofactor, collaborates with multiple HOX and NUP98-HOX fusion proteins to accelerate the onset of acute myeloid leukemia (AML) through largely unknown molecular mechanisms...
  91. ncbi Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias
    C G Mullighan
    Department of Pathology, St Jude Children s Research Hospital, Memphis, TN, USA
    Leukemia 21:2000-9. 2007
    ..These findings suggest that mutated NPM1 leads to dysregulated HOX expression via a different mechanism than MLL rearrangement...
  92. ncbi The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation
    Sung A Lee
    Department of Radiation Medicine, Georgetown University Medical Center, Washington, DC 20057 1482, USA
    J Biol Chem 282:15271-83. 2007
    ..Taken together, our data suggest that sangivamycin induces mitochondria-mediated apoptotic cell death of MCF7/ADR cells via activation of JNK in a protein kinase Cdelta-dependent manner...
  93. pmc Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family
    S Fears
    Department of Molecular Genetics and Cellular Biology, The University of Chicago, IL 60637, USA
    Proc Natl Acad Sci U S A 93:1642-7. 1996
    ..These results are important in view of the fact that EVI1 and MDS1 are involved in leukemia associated with chromosomal translocation breakpoints in the region between these genes...
  94. ncbi Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations
    Masao Mizuki
    Department of Medicine, Hematology Oncology, University of Munster, Germany
    Blood 101:3164-73. 2003
    ..The identification of the transcriptional program induced by ITD mutations should ease the development of specific therapies...
  95. ncbi ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease
    P F Erickson
    Division of Medical Oncology, University of Colorado Medical School, Denver 80262, USA
    Blood 88:1813-23. 1996
    ..Also, because ETO would not be exclusively expressed as part of chimeric AML1/ETO in leukemic patients, its presence cannot be used to monitor t(8;21) AML residual disease...
  96. ncbi DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1
    K Kannan
    Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel
    Oncogene 20:3449-55. 2001
    ..The proapoptotic genes induced only in LTR6 cells like Apaf-1, Sumo-1 and gelsolin among others may suggest a possible explanation for apoptosis in LTR6 cells...
  97. ncbi Expression of sorcin predicts poor outcome in acute myeloid leukemia
    Yaohong Tan
    State Key Laboratory of Experimental Hematology, Institute of Hematology, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin 300020, China
    Leuk Res 27:125-31. 2003
    ..Our results indicated that sorcin might be one of the factors that contributes to drug resistance of AML patients...
  98. ncbi Beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1)
    Yutaka Masuda
    Laboratory of Biological Chemistry, School of Pharmaceutical Sciences, Showa University, Tokyo 142 8555, Japan
    Oncogene 22:1012-23. 2003
    ..These results suggest that suppression of the activity of PLK1 via inhibition of tyrosine kinase activity by beta-HIVS might play a critical role in the induction of apoptosis...
  99. ncbi In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity
    C Wuchter
    Department of Hematology, Oncology, and Tumor Immunology, Robert Rossle Clinic, Charite, Humboldt University of Berlin, Germany
    Leukemia 15:921-8. 2001
    ..The observed sensitization of leukemic cells to TRAIL by doxorubicin in vitro indicates that TRAIL should be further evaluated as to its possible role as an in vivo cotherapeutic in acute leukemia...
  100. ncbi Multidrug resistance modulators PSC 833 and CsA show differential capacity to induce apoptosis in lymphoid leukemia cell lines independently of their MDR phenotype
    Eloisi C Lopes
    Department of Immunology, School of Pharmacy and Biochemistry, University of Buenos Aires UBA IDEHU CONICET, Junin 956 4 piso, 1113, Buenos Aires, Argentina
    Leuk Res 27:413-23. 2003
    ..1 microg ml(-1)) or by direct impact on the cells through induction of apoptosis (1 microg ml(-1)), in the latter case through a mechanism that might act independent of the Bcl-2 family proteins...
  101. ncbi Chromatin remodeling gene SMARCA5 is dysregulated in primitive hematopoietic cells of acute leukemia
    T Stopka
    Institute of Hematology and Blood Transfusion and Department of Pathophysiology, First Medical Faculty, Charles University, Prague, Czech Republic
    Leukemia 14:1247-52. 2000
    ..In CD34+ AML progenitors over-expression of SMARCA5 may thus dysregulate the genetic program required for normal differentiation...

Research Grants40

  1. Examination of imatinib mesylate resistance in CML
    Vivian Oehler; Fiscal Year: 2008
    ..The gene expression pattern of the relapsed sample will be compared with the corresponding diagnostic sample. We hypothesize that the evolution of a previously undetected clone is the mechanism of relapse. ..
  2. AFB1 AND P53 CARCINOGENESIS IN HBSAG TRANSGENIC MICE
    Stewart Sell; Fiscal Year: 2002
    ..These studies should lead to an understanding of how each of these risk factors affect hepatocyte proliferation and how these effects contribute to AFB1 hepatocarcinogenesis. ..
  3. A NOVEL VECTOR FOR VACCINATION AGAINST HEPETITIS C VIRUS
    Nikolaus Osterrieder; Fiscal Year: 2006
    ..The tests will include ELISPOT and CTL assays in the context of a human class I allele using HLA-A2.1 transgenic mice. ..
  4. Novel Functions for Telomerase Enzyme Complex in Vivo
    Steven Artandi; Fiscal Year: 2005
    ..Through analysis of a conditional knockout mouse, we will determine the role of endogenous telomerase in cells in culture and in stern/progenitor compartments in vivo. ..
  5. TARGETED MANIPULATION OF STEM CELLS FOR AIDS THERAPY
    David T Scadden; Fiscal Year: 2010
    ..Success of this project will provide both in depth understanding of key regulatory pathways for adult HSC and create targeted approaches to manipulate stem cell self-renewal for therapeutic purposes. ..
  6. Characterization of the 11q13 Amplicon in Oral Cancer
    Susanne Gollin; Fiscal Year: 2006
    ..The results of this study may lead to targeted methods for prevention, early detection, therapy, and/or eradication of cells harboring gene amplification. ..
  7. Retinoic Acid Regulated Cell Differentiation: BLR1 Rcptr
    Andrew Yen; Fiscal Year: 2005
    ..It has the implication that the ultimate effects of RA can be governed by relevant growth factors signaling through their cognate receptors. ..
  8. Prognosis in childhood ALL
    URSULA KEES; Fiscal Year: 2006
    ....
  9. Development of SL-101, An Immunotoxin that Targets Cancer Stem Cells
    Malcolm Moore; Fiscal Year: 2006
    ..This Phase I STTR grant will cover the development of SL-101 through key phases of pre-clinical development. [unreadable] [unreadable] [unreadable]..
  10. Human TNFa-Induced Pre-B Cell Bone Marrow Emigrants
    MARC LEVESQUE; Fiscal Year: 2007
    ..We will also determine whether anti-TNFa therapy is associated with reductions in peripheral populations of TNFa- induced pre-B cell bone marrow emigrants in RA patients. [unreadable] [unreadable] [unreadable]..
  11. 2007 Cell Biology of Megakaryocytes and Platelets GRC
    Kenneth Kaushansky; Fiscal Year: 2007
    ..e. speakers, discussion leaders, postdoctoral fellows, students, etc.) at this important scientific meeting. [unreadable] [unreadable] [unreadable]..
  12. Control of lymphomagenesis by ATM through ROS, mTOR and PP2A signaling
    Mingshan Yan; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  13. STEM CELLS AND AGING
    Stewart Sell; Fiscal Year: 2008
    ..The results of these experiments should provide critical proof for one of the most important hypothetical properties of adult stem cells. ..
  14. STEM CELLS AND HEPATOCARCINOGENESIS
    Stewart Sell; Fiscal Year: 2009
    ..Knowledge of the cellular origin of cancer is critical for understanding how cancer evolves and for developing prevention strategies. ..
  15. HoxA10 Function During Myeloid Differentiation
    Elizabeth Eklund; Fiscal Year: 2006
    ..These investigations will identify the molecular mechanisms of target gene regulation by HoxA10, which may suggest a role for HoxA10 in differentiation block in myeloid leukemia. ..
  16. GROWTH FACTORS IN NORMAL AND NEOPLASTIC HEMATOPOIESIS
    Kenneth Kaushansky; Fiscal Year: 2006
    ....
  17. TOPOISOMERASES IN RETINOID INDUCED DIFFERENTIATION
    Andrew Yen; Fiscal Year: 2003
    ..Andrew Yen, who brings expertise on the molecular and cellular biology of retinoic acid-induced myeloid differentiation. ..
  18. POST TRANSCRIPTIONAL CONTROL OF THE HUMAN N MYC GENE
    William Carroll; Fiscal Year: 2002
    ....
  19. Phase II Trial of Thalidomide in Primary Amyloidosis
    Angela Dispenzieri; Fiscal Year: 2002
    ..The ultimate goal of the proposed studies is to improve the prognosis of patient with this fatal disease. ..
  20. TELOMERE DYSFUNCTION, GENOMIC INSTABILITY AND CANCER
    Steven Artandi; Fiscal Year: 2005
    ..Transplantation experiments using this model will reveal if the effect on tumor biology is a cell autonomous one. ..
  21. FACTORS INFLUENCING STEM CELL AND PLATELET PRODUCTION
    Malcolm Moore; Fiscal Year: 2002
    ..e., adult populations acquiring features of neonatal cells, or whether there is a tendency for "immortalized" cells to undergo neoplastic transformation. ..
  22. VZV BACs: New Tools for Pathogenesis Research
    Nikolaus Osterrieder; Fiscal Year: 2005
    ..B-scid/beige mice, and infected MeWo or MeWo-9 cells will be used to inoculate the grafts. Virus replication in the implants will be examined by virus titrations, real-time PCR, histopathology and immunohistochemistry. ..
  23. Cell biology of megakaryocytes and platelets 2005
    Kenneth Kaushansky; Fiscal Year: 2005
    ..This application is a request for partial funds to support the attendance of speakers and discussion leaders, and selected postdoctoral fellows and students at this important new meeting. ..
  24. Prevention of Chronic Lymphocytic Leukemia (CLL)
    MARC LEVESQUE; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  25. GENES INVOLVED IN AIDS LYMPHOMAGENESIS
    Michael Teitell; Fiscal Year: 2002
    ..Genes with significant involvement in the etiology and/or progression of lymphomagenesis, or those with reproducible in vitro biochemical effects, will be further characterized by molecular methods. ..
  26. FUSION GENES IN LEUKEMIA--DETERMINING SIGNIFICANCE
    Mignon Loh; Fiscal Year: 2003
    ..abstract_text> ..
  27. Chemical Genomics Approach to Leukemia Differentiation
    Kimberly Stegmaier; Fiscal Year: 2007
    ..These candidate compounds, as well as an improved understanding of myeloid leukemia differentiation, should help direct us to potential therapeutic agents for AML. ..
  28. BOSTON AIDS MALIGNANCY CONSORTIUM
    David Scadden; Fiscal Year: 2004
    ..Furthering the efforts of the BAMC within the national consortium is the focus of this proposal. ..
  29. DIFFERENTIATION OF BLOOD STEM CELLS INTO LIVER CELLS
    Stewart Sell; Fiscal Year: 2005
    ..If this project is successful, it would overcome a major hurdle in the possible use of hepatic stem cells for treatment of liver failure or ex vivo gene therapy. ..
  30. HEPTOCYTE PROLIFERATION AND AFLATOXIN METABOLISM
    Stewart Sell; Fiscal Year: 2004
    ..the effect Of HBV associated injury and AFB I hepatocarcinogensis in these mice. In Specific Aim 3, the effect of HBV associated injury and AFB1 hepatocarcinogenesis in these mice will be examined. ..
  31. ICSBP Function During Myeloid Differentiation
    Elizabeth Eklund; Fiscal Year: 2006
    ..These studies will determine if ICSBP tyrosine phosphorylation is necessary for myeloid differentiation and leukemia suppression, providing a unique model to dissect early events in the evolution of myeloid malignancy. ..
  32. FLT3 GENOTYPES IN ACUTE MYELOID LEUKEMIA
    Susan Whitman; Fiscal Year: 2006
    ..abstract_text> ..
  33. FLUORESCENCE ACTIVATED CELL SORTER
    Andrew Yen; Fiscal Year: 2004
    ..The instrument requested is a Dako-Cytomation basic MoFlo plus a UV-vis, vis, and HeNe laser to provide independent UV, vis/488, and red excitation. ..
  34. Ras Pathway Mutations in Human Leukemia
    Mignon Loh; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  35. Bcr-Abl RNA levels to monitor STI571 leukemia therapy
    Richard Press; Fiscal Year: 2004
    ..abstract_text> ..
  36. Phase I Clinical Trials of Anti-Cancer Agents
    Francis Giles; Fiscal Year: 2007
    ..abstract_text> ..
  37. Hedgehog signaling as a novel regulator of hematopoiesis
    Iannis Aifantis; Fiscal Year: 2007
    ..We will complement these experiments with the study of novel Hh activating mouse mutants in which we will define the exact role of the Gli factors in the regulation of mammalian lymphopoiesis and hematopoiesis. ..
  38. Examination of FLT3 Mutations in Acute Myeloid Leukemia
    Derek Stirewalt; Fiscal Year: 2006
    ..Together, the research proposal and educational program provide Dc Stirewalt with the skills to become an independent clinical investigator. ..